The Science Behind Brain & Cognitive Supplements

Therapeutic dose: 1,000–2,000 mg/day DHA (or 2,000–3,000 mg combined EPA+DHA)

• 2022 meta-analysis of 22 RCTs found omega-3 supplementation (primarily DHA) significantly improved episodic memory in adults with mild cognitive impairment, though effects in cognitively healthy adults were smaller.PubMed ↗
• 2020 meta-analysis of 38 RCTs found DHA-dominant formulations improved attention and processing speed in adults. EPA-dominant formulations showed more benefit for mood than cognition.PubMed ↗
• DHA constitutes ~40% of polyunsaturated fatty acids in the brain and ~60% in retinal photoreceptors. It is structurally essential for membrane fluidity, synaptic signaling, and neurogenesis.
• VITAL-Cog substudy (2022, 2,262 participants) found no benefit of 1g/day omega-3 for cognitive decline in healthy older adults over 5 years — consistent with the pattern that benefits are clearest in those with low baseline intake or mild impairment.PubMed ↗
• Dose matters: most positive trials used ≥1g DHA/day. Typical fish oil capsules provide only 120–250mg DHA — likely insufficient for cognitive benefit.

Therapeutic dose: 3,000–5,000 mg/day (creatine monohydrate)

• Avgerinos et al. (2018) meta-analysis of 6 RCTs (281 participants) found creatine supplementation significantly improved short-term memory and reasoning, particularly in stressed populations (sleep deprivation, aging).PubMed ↗
• 2022 RCT found 5g/day creatine for 6 weeks improved cognitive performance under sleep deprivation — consistent with its role as a brain energy buffer.PubMed ↗
• The brain consumes ~20% of total body energy but constitutes only 2% of body mass. Creatine provides rapid ATP regeneration via the phosphocreatine shuttle — critical during cognitively demanding tasks.
• Vegetarians show larger cognitive benefits from creatine supplementation than omnivores, likely because they have lower baseline brain creatine stores (creatine is primarily obtained from meat).
• Creatine monohydrate is the only well-studied form. Buffered creatine, creatine HCl, and other variants lack evidence of superiority. Loading phase (20g/day for 5 days) is optional — 3–5g/day reaches saturation in ~4 weeks.

Therapeutic dose: 300–600 mg/day (standardized to 50% bacosides)

• Kongkeaw et al. (2014) meta-analysis of 9 RCTs (518 participants) found Bacopa monnieri significantly improved attention, cognitive processing speed, and working memory compared to placebo.PubMed ↗
• 2021 systematic review confirmed consistent improvements in memory acquisition and retention across 12 RCTs. Effects typically emerge at 8–12 weeks — shorter trials show minimal benefit.PubMed ↗
• 2014 RCT (60 medical students) found 300 mg/day Bacopa for 6 weeks improved memory, attention, and reduced impulsivity. One of several studies in young, healthy adults — unusual for nootropic compounds.PubMed ↗
• Mechanism: bacosides enhance synaptic communication by modulating acetylcholine, GABA, and serotonin. Also upregulates BDNF and has antioxidant effects in hippocampal neurons.
• GI side effects (nausea, cramping) are common, especially on empty stomach. Best taken with food. Effects reverse after discontinuation — requires ongoing use.

Therapeutic dose: 250–500 mg/day citicoline (CDP-choline)

• 2005 Cochrane review of 14 RCTs found citicoline improved memory, behavior, and global impression in elderly patients with cognitive impairment (dementia, cerebrovascular disease). Quality of trials was variable.PubMed ↗
• 2015 RCT (100 healthy older adults) found citicoline 500 mg/day for 12 weeks improved episodic memory and overall memory performance.PubMed ↗
• Choline is an essential nutrient — 90% of Americans are below adequate intake (550 mg/day for men, 425 mg for women). Supplementation primarily addresses a widespread dietary gap.
• Citicoline (CDP-choline) donates choline for acetylcholine synthesis and cytidine for neuronal membrane repair. It is the preferred nootropic form over choline bitartrate, which has poor brain penetration.

Therapeutic dose: 300–600 mg/day (nootropic); 1,200 mg/day (clinical dementia trials)

• 2003 meta-analysis of 13 clinical trials (4,054 patients) found alpha-GPC improved cognitive scores in patients with dementia and cerebrovascular disease. Most trials used 1,200 mg/day.PubMed ↗
• Alpha-GPC delivers ~40% choline by weight — the highest of any choline supplement form. Crosses the blood-brain barrier efficiently and directly contributes to phosphatidylcholine synthesis in neuronal membranes.
• 2021 Korean observational study raised concern about alpha-GPC use being associated with stroke risk in older adults. This requires further investigation in RCTs but is worth noting.PubMed ↗

Therapeutic dose: 100–300 mg/day

• FDA allows a qualified health claim (2003): 'Phosphatidylserine may reduce the risk of cognitive dysfunction in the elderly' — though with the caveat that evidence is limited and preliminary.
• 2010 RCT (78 elderly adults with mild cognitive impairment) found 300 mg/day soy-derived phosphatidylserine for 6 months significantly improved memory recognition and recall.PubMed ↗
• Earlier trials used bovine brain-derived PS (now unavailable due to BSE concerns). Soy-derived PS has replaced it but may not be identical in efficacy — the lipid tail composition differs.
• Phosphatidylserine is a structural component of neuronal membranes, concentrated at synaptic terminals. It facilitates neurotransmitter release, receptor function, and signal transduction.

Therapeutic dose: 500–3,000 mg/day (fruiting body extract)

• 2009 RCT (30 Japanese adults with mild cognitive impairment) found 3g/day lion's mane for 16 weeks significantly improved cognitive function scores. Benefits disappeared 4 weeks after discontinuation.PubMed ↗
• 2020 RCT (77 overweight adults) found lion's mane 1,600 mg/day for 8 weeks improved cognitive performance (speed and accuracy) in a complex reaction time task.PubMed ↗
• Unique mechanism: hericenones and erinacines stimulate nerve growth factor (NGF) synthesis in vitro. NGF is critical for neuronal survival, growth, and differentiation. No other common supplement has this mechanism.
• Limitation: existing RCTs are small (n < 80), short-term, and mostly from Japan. Larger, longer, independent trials are needed. Extract standardization varies widely between products.

Therapeutic dose: 500–1,500 mg/day standard; 80–400 mg/day enhanced forms (Theracurmin, Longvida)

• 2018 RCT (40 adults aged 51–84) found Theracurmin 90 mg 2x/day for 18 months significantly improved memory and attention, and PET scans showed reduced amyloid and tau accumulation in brain regions modulating mood and memory.PubMed ↗
• 2020 meta-analysis of 10 RCTs found curcumin supplementation significantly improved cognitive function and reduced cognitive decline markers in middle-aged and older adults.PubMed ↗
• Mechanism: anti-inflammatory (NF-kB inhibition), antioxidant, enhances BDNF expression, and binds amyloid-beta aggregates. The combination of mechanisms is uniquely relevant to neurodegeneration.
• Standard curcumin has 1–2% oral bioavailability. Enhanced forms are essential for brain effects: Theracurmin (27x), Longvida (65x), Meriva (29x). Trials using standard turmeric powder typically fail.

Therapeutic dose: 200–600 mg/day (standardized to 3% rosavins, 1% salidroside)

• 2012 systematic review of 11 RCTs found Rhodiola rosea improved physical and mental fatigue, with the strongest evidence for cognitive function under stress (exam periods, night shifts, military exercises).PubMed ↗
• 2000 RCT (161 military cadets) found 370 mg/day Rhodiola for 5 days during sleep deprivation significantly improved cognitive function, associative thinking, and short-term memory.PubMed ↗
• Adaptogenic mechanism: modulates HPA axis, regulates cortisol, and enhances monoamine neurotransmitter activity (serotonin, dopamine, norepinephrine). Acute effects on fatigue appear within hours.
• Limitation: most trials are short-term (1–6 weeks) and measure cognitive function under stress rather than long-term cognitive health. Baseline cognitive enhancement in unstressed individuals is unproven.

Therapeutic dose: 500–2,000 mg (acute, before stressful tasks)

• 2015 review of military and lab studies found L-tyrosine (150 mg/kg) improved cognitive performance under acute stress (cold exposure, sleep deprivation, multitasking), but effects are short-lived and dose-timing dependent.PubMed ↗
• Mechanism: precursor to dopamine, norepinephrine, and epinephrine. Under stress, catecholamine turnover increases rapidly — tyrosine supplementation maintains production when demand exceeds synthesis capacity.
• No evidence supports daily tyrosine for long-term cognitive enhancement. Benefits are limited to acute stress resilience. Excess tyrosine is simply catabolized — the body does not store it.

Therapeutic dose: 500–1,000 mg/day blueberry extract (equivalent to ~1 cup fresh blueberries)

• 2017 RCT (26 healthy older adults) found concentrated blueberry juice (equivalent to 230g fresh berries/day) for 12 weeks improved brain activation on fMRI and working memory performance.PubMed ↗
• Nurses' Health Study (observational, 16,010 women) found higher blueberry/strawberry intake was associated with slower cognitive decline — equivalent to delaying aging by up to 2.5 years.PubMed ↗
• Anthocyanins cross the blood-brain barrier and accumulate in hippocampus and cortex. They improve neuronal signaling, reduce neuroinflammation, and enhance cerebral blood flow. But RCTs are small and short-term.

Therapeutic dose: 1,000–3,000 mg/day

• 2023 Science paper found taurine levels decline with age in humans and animals. Taurine supplementation reversed age-related cognitive decline in mice and improved memory. Human cognitive trials are lacking.PubMed ↗
• Taurine is the most abundant free amino acid in the brain. It acts as an inhibitory neuromodulator (GABA-A receptor agonist), osmoregulator, and antioxidant in neurons.
• Limited human data: small studies show acute improvements in reaction time and attention (often confounded by caffeine in energy drink studies). No long-term cognitive RCTs in humans exist.

Therapeutic dose: 15–30 mL/day (15–20g MCTs, primarily C8 caprylic acid)

• 2009 RCT (152 mild-to-moderate Alzheimer's patients) found MCT-derived ketones improved cognitive scores in APOE4-negative patients but not in APOE4 carriers.PubMed ↗
• Mechanism: MCTs are rapidly converted to ketone bodies by the liver. Ketones provide an alternative brain fuel source when glucose metabolism is impaired (as in Alzheimer's and aging).
• No evidence for cognitive enhancement in healthy adults with normal glucose metabolism. GI tolerance limits dosing — start at 5 mL/day and titrate up. C8 (caprylic acid) produces more ketones than C10 or C12.

Therapeutic dose: 5–20 mg/day lithium orotate (microdose; distinct from psychiatric lithium at 300–1,200 mg/day)

• Multiple epidemiological studies found higher lithium levels in drinking water were associated with lower rates of dementia, suicide, and all-cause mortality. But association does not prove causation.PubMed ↗
• 2019 review of neuroprotective mechanisms: lithium inhibits GSK-3beta (implicated in Alzheimer's tau pathology), enhances autophagy, increases BDNF, and reduces neuroinflammation — all at concentrations achievable with microdosing.PubMed ↗
• No RCTs exist for low-dose lithium orotate as a cognitive supplement. The evidence is extrapolated from psychiatric lithium (used for bipolar disorder) and ecological studies. This remains highly speculative for supplementation.

Therapeutic dose: 500–1,000 mcg/day (methylcobalamin or cyanocobalamin)

• Cochrane review (2003, updated 2009) of 3 RCTs found no evidence that vitamin B12 supplementation improved cognitive function in older adults with or without dementia — when B12 status was not specifically deficient.PubMed ↗
• B12 deficiency causes irreversible neurological damage (subacute combined degeneration). At-risk groups: vegans, elderly (10–30% have low B12 due to malabsorption), those on metformin or PPIs.
• VITACOG trial found B vitamins (including B12) slowed brain atrophy by 30% in elderly with elevated homocysteine and MCI — but the effect appears driven by correcting deficiency, not by supplementation in replete individuals.PubMed ↗

Therapeutic dose: 1.3–10 mg/day (P-5-P is the active form)

• B6 is required for synthesis of serotonin, dopamine, GABA, and norepinephrine. Deficiency causes confusion, depression, and peripheral neuropathy. But deficiency is uncommon in developed countries.
• 2022 RCT (478 young adults) found 100 mg/day vitamin B6 for one month slightly reduced self-reported anxiety, potentially via increased GABA synthesis. Effects on cognitive performance were not measured.PubMed ↗
• No evidence supports B6 supplementation for cognitive enhancement in non-deficient individuals. High-dose B6 (>200 mg/day long-term) causes peripheral sensory neuropathy — the very symptom it prevents when correcting deficiency.

Therapeutic dose: 400–800 mcg/day DFE (as methylfolate for those with MTHFR variants)

• FACIT trial (2007, 818 adults) found 800 mcg/day folic acid for 3 years improved memory, processing speed, and sensorimotor speed compared to placebo. One of the few positive RCTs — but participants had elevated homocysteine.PubMed ↗
• Folate, B12, and B6 work together to recycle homocysteine. Elevated homocysteine is associated with cognitive decline and brain atrophy. B-vitamin supplementation appears to benefit cognition primarily by lowering homocysteine in those with elevated levels.
• ~30% of the population carries MTHFR C677T variant with reduced ability to convert folic acid to active methylfolate. For these individuals, methylfolate (5-MTHF) supplementation may be preferable to folic acid.